全文获取类型
收费全文 | 997篇 |
免费 | 57篇 |
国内免费 | 2篇 |
专业分类
耳鼻咽喉 | 11篇 |
儿科学 | 81篇 |
妇产科学 | 73篇 |
基础医学 | 97篇 |
口腔科学 | 8篇 |
临床医学 | 93篇 |
内科学 | 208篇 |
皮肤病学 | 39篇 |
神经病学 | 147篇 |
特种医学 | 48篇 |
外科学 | 128篇 |
综合类 | 2篇 |
一般理论 | 1篇 |
预防医学 | 51篇 |
眼科学 | 9篇 |
药学 | 38篇 |
中国医学 | 1篇 |
肿瘤学 | 21篇 |
出版年
2023年 | 10篇 |
2022年 | 10篇 |
2021年 | 20篇 |
2020年 | 12篇 |
2019年 | 24篇 |
2018年 | 20篇 |
2017年 | 15篇 |
2016年 | 16篇 |
2015年 | 21篇 |
2014年 | 32篇 |
2013年 | 49篇 |
2012年 | 68篇 |
2011年 | 71篇 |
2010年 | 42篇 |
2009年 | 23篇 |
2008年 | 45篇 |
2007年 | 47篇 |
2006年 | 42篇 |
2005年 | 36篇 |
2004年 | 40篇 |
2003年 | 47篇 |
2002年 | 34篇 |
2001年 | 29篇 |
2000年 | 24篇 |
1999年 | 22篇 |
1998年 | 8篇 |
1996年 | 6篇 |
1995年 | 5篇 |
1994年 | 8篇 |
1993年 | 5篇 |
1992年 | 14篇 |
1991年 | 12篇 |
1990年 | 20篇 |
1989年 | 15篇 |
1988年 | 14篇 |
1987年 | 14篇 |
1986年 | 8篇 |
1985年 | 10篇 |
1984年 | 13篇 |
1983年 | 8篇 |
1981年 | 7篇 |
1979年 | 8篇 |
1978年 | 6篇 |
1976年 | 5篇 |
1975年 | 4篇 |
1974年 | 9篇 |
1973年 | 4篇 |
1972年 | 5篇 |
1886年 | 4篇 |
1885年 | 13篇 |
排序方式: 共有1056条查询结果,搜索用时 8 毫秒
31.
32.
33.
BACKGROUND: Hyperthyroidism has been associated with liver function abnormalities; however, cholestasis as the presenting feature of adolescent Graves' disease has not been previously reported. PATIENT SUMMARY: The patient was a 17-year-old girl who presented with severe cholestasis and was found to have Graves' disease. She also had a positive hepatitis A immunoglobulin M antibody but her clinical course, the liver histopathology, and her mildly elevated transaminases indicated that the acute hepatitis A infection was not dominant at the time of presentation with severe cholestasis. Other causes of cholestasis, including congestive heart failure, autoimmune hepatitis, and viral infection, were excluded. Treatment with methimazole resolved the hyperthyroidism, and the cholestasis improved, as well. CONCLUSION: Severe cholestasis is a rare presenting feature of Graves' disease. With careful monitoring, methimazole can be used to treat the hyperthyroidism in the setting of cholestasis. 相似文献
34.
BACKGROUND: Clinical evidence points to patient-perceived difficulties and compliance problems in implementing early insulin therapy. Therefore, individual treatment aims are necessary to optimize diabetes therapy, as currently acknowledged by the new ADA/EASD guidelines. Better characterization of patient-perceived difficulties in the implementation of early insulin treatment may contribute to improved compliance and optimal tailoring of treatment regimens for the individual patient. OBJECTIVES: To assess differences in quality of life (QoL) and patient-perceived difficulties in health care with every addition of oral hypoglycemic agents (OHAs) and insulin therapy. METHODS: The analysis was conducted on a cross-sectional sample of 714 diabetic patients treated with OHAs or with insulin once or twice daily. Differences in diabetes-specific QoL, overall QoL, and perception of difficulties associated with specific diabetes treatment attributes were evaluated using trend analysis and comparisons between groups. The contribution of each diabetes treatment attribute to QoL measures and glycemic control was also assessed. RESULTS: No significant differences were found in QoL measures among patients treated exclusively with OHAs when these patients were assessed by the number of oral agents, irrespective of the degree of glycemic control. Better controlled patients treated with 2 OHAs, compared with poorly controlled patients treated with a single OHA, had a lower perception of difficulties associated with diabetes treatment attributes. Poorly controlled patients treated with 2 OHAs and better controlled patients treated with 3 OHAs had similar QoL and perceived difficulties with care. However, the insulin-based alternative was consistently associated with a significantly higher perception of pain and lower overall QoL when compared with the oral regimens. Multivariate models accounted for 52% and 32% of the variance in QoL measures. CONCLUSIONS: From the patients’ perspective, oral therapy is the preferred strategy for attaining the treatment goals since the addition of OHAs was not associated with lower QoL or patient-perceived difficulties with care. If early insulin treatment is considered, physicians should address specific diabetes treatment characteristics, mainly the issue of pain, to promote improved QoL and disease control. 相似文献
35.
Comprehensive motion‐compensated highly accelerated 4D flow MRI with ferumoxytol enhancement for pediatric congenital heart disease 下载免费PDF全文
36.
37.
End-of-life care can be delivered in a variety of settings, whereby the majority of terminally-ill cancer patients prefer to die at home. The aim of our study is to evaluate health services utilisation during the last year of life, and to compare terminally ill patients who have received home-specialised palliative care services (HSPCS) with patients who died receiving home non-specialised palliative care services. The study included 120 and 515 patients, respectively, who died between 1999-2000. Age and gender distribution were similar in both groups. During the last year of life, mean health services cost per person among the HSPCS group was lower by more then 30% (P < 0.005). The median cost per patient was as low as one-fifth in the last month. Men and the older age group of 65 and above, cost significantly less compared with women and younger patients, respectively, regardless of provider setting. The main differences in health services utilisation were in hospitalisations and oncology treatments (P < 0.01 and P < 0.05, respectively). 相似文献
38.
39.
Tamir Bloom MD Caixia Zhao MD Alpesh Mehta MD Uma Thakur MD John Koerner MD Sanjeev Sabharwal MD MPH 《Clinical orthopaedics and related research》2014,472(12):3779-3788